RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 12
IS 20
SP 9
OP 10
DO 10.1177/155989771220005
UL http://mdc.sagepub.com/content/12/20/9.2.abstract
AB In 2005, data from 3 large randomized trials demonstrated that 1 year of trastuzumab treatment provided a statistically significant disease-free survival benefit compared with no trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer [Piccart-Gebhart MJ et al. N Engl J Med 2005]. One of these studies, the Trastuzumab in Treating Women with Primary Breast Cancer [HERceptin Adjuvant (HERA); NCT00045032] trial, continued trastuzumab therapy to assess whether 2 years of treatment was superior to 1 year. This article provides an update of the HERA trial after 8 years of median follow-up.